|
1
|
Eslam M, Sanyal AJ and George J:
International Consensus Panel. MAFLD: A consensus-driven proposed
nomenclature for metabolic associated fatty liver disease.
Gastroenterology. 158:1999–2014.e1. 2020.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Eslam M, Newsome PN, Sarin SK, Anstee QM,
Targher G, Romero-Gomez M, Zelber-Sagi S, Wai-Sun Wong V, Dufour
JF, Schattenberg JM, et al: A new definition for metabolic
dysfunction-associated fatty liver disease: An international expert
consensus statement. J Hepatol. 73:202–209. 2020.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Männistö VT, Salomaa V, Färkkilä M, Jula
A, Männistö S, Erlund I, Sundvall J, Lundqvist A, Perola M and
Åberg F: Incidence of liver-related morbidity and mortality in a
population cohort of non-alcoholic fatty liver disease. Liver Int.
41:2590–2600. 2021.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Calzadilla Bertot L and Adams LA: The
natural course of non-alcoholic fatty liver disease. Int J Mol Sci.
17(774)2016.PubMed/NCBI View Article : Google Scholar
|
|
5
|
National Workshop on Fatty Liver and
Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese
Medical Association; Fatty Liver Expert Committee, Chinese Medical
Doctor Association. Guidelines of prevention and treatment for
nonalcoholic fatty liver disease: A 2018 update. Zhonghua Gan Zang
Bing Za Zhi. 26:195–203. 2018.PubMed/NCBI View Article : Google Scholar : (In Chinese).
|
|
6
|
Li B, Zhang C and Zhan YT: Nonalcoholic
fatty liver disease cirrhosis: A review of its epidemiology, risk
factors, clinical presentation, diagnosis, management, and
prognosis. Can J Gastroenterol Hepatol.
2018(2784537)2018.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Cobbina E and Akhlaghi F: Non-alcoholic
fatty liver disease (NAFLD)-pathogenesis, classification, and
effect on drug metabolizing enzymes and transporters. Drug Metab
Rev. 49:197–211. 2017.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Sangouni AA and Ghavamzadeh S: A review of
synbiotic efficacy in non-alcoholic fatty liver disease as a
therapeutic approach. Diabetes Metab Syndr. 13:2917–2922.
2019.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Tarantino G, Citro V and Capone D:
Nonalcoholic fatty liver disease: A challenge from mechanisms to
therapy. J Clin Med. 9(15)2019.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Safari Z and Gérard P: The links between
the gut microbiome and non-alcoholic fatty liver disease (NAFLD).
Cell Mol Life Sci. 76:1541–1558. 2019.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Astbury S, Atallah E, Vijay A, Aithal GP,
Grove JI and Valdes AM: Lower gut microbiome diversity and higher
abundance of proinflammatory genus Collinsella are associated with
biopsy-proven nonalcoholic steatohepatitis. Gut Microbes.
11:569–580. 2020.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Miura K and Ohnishi H: Role of gut
microbiota and Toll-like receptors in nonalcoholic fatty liver
disease. World J Gastroenterol. 20:7381–7391. 2014.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Csak T, Ganz M, Pespisa J, Kodys K,
Dolganiuc A and Szabo G: Fatty acid and endotoxin activate
inflammasomes in mouse hepatocytes that release danger signals to
stimulate immune cells. Hepatology. 54:133–144. 2011.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Silva YP, Bernardi A and Frozza RL: The
role of short-chain fatty acids from gut microbiota in gut-brain
communication. Front Endocrinol (Lausanne). 11(25)2020.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Chan JC, Kioh DY, Yap GC, Lee BW and Chan
EC: A novel LCMSMS method for quantitative measurement of
short-chain fatty acids in human stool derivatized with
12C- and 13C-labelled aniline. J Pharm Biomed
Anal. 138:43–53. 2017.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Canfora EE, Meex RCR, Venema K and Blaak
EE: Gut microbial metabolites in obesity, NAFLD and T2DM. Nat Rev
Endocrinol. 15:261–273. 2019.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Koh A, De Vadder F, Kovatcheva-Datchary P
and Bäckhed F: From dietary fiber to host physiology: Short-chain
fatty acids as key bacterial metabolites. Cell. 165:1332–1345.
2016.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Aragonès G, González-García S, Aguilar C,
Richart C and Auguet T: Gut microbiota-derived mediators as
potential markers in nonalcoholic fatty liver disease. Biomed Res
Int. 2019(8507583)2019.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Schilderink R, Verseijden C and de Jonge
WJ: Dietary inhibitors of histone deacetylases in intestinal
immunity and homeostasis. Front Immunol. 4(226)2013.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Stojsavljević S, Gomerčić Palčić M,
Virović Jukić L, Smirčić Duvnjak L and Duvnjak M: Adipokines and
proinflammatory cytokines, the key mediators in the pathogenesis of
nonalcoholic fatty liver disease. World J Gastroenterol.
20:18070–18091. 2014.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Michail S, Lin M, Frey MR, Fanter R, Paliy
O, Hilbush B and Reo NV: Altered gut microbial energy and
metabolism in children with non-alcoholic fatty liver disease. FEMS
Microbiol Ecol. 91:1–9. 2015.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Rau M, Rehman A, Dittrich M, Groen AK,
Hermanns HM, Seyfried F, Beyersdorf N, Dandekar T, Rosenstiel P and
Geier A: Fecal SCFAs and SCFA-producing bacteria in gut microbiome
of human NAFLD as a putative link to systemic T-cell activation and
advanced disease. United European Gastroenterol J. 6:1496–1507.
2018.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Kundi ZM, Lee JC, Pihlajamäki J, Chan CB,
Leung KS, So SSY, Nordlund E, Kolehmainen M and El-Nezami H:
Dietary fiber from oat and rye brans ameliorate western
diet-induced body weight gain and hepatic inflammation by the
modulation of short-chain fatty acids, bile acids, and tryptophan
metabolism. Mol Nutr Food Res. 65(e1900580)2021.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Svegliati-Baroni G, Saccomanno S,
Rychlicki C, Agostinelli L, De Minicis S, Candelaresi C, Faraci G,
Pacetti D, Vivarelli M, Nicolini D, et al: Glucagon-like peptide-1
receptor activation stimulates hepatic lipid oxidation and restores
hepatic signalling alteration induced by a high-fat diet in
nonalcoholic steatohepatitis. Liver Int. 31:1285–1297.
2011.PubMed/NCBI View Article : Google Scholar
|
|
25
|
He J, Zhang P, Shen L, Niu L, Tan Y, Chen
L, Zhao Y, Bai L, Hao X, Li X, et al: Short-Chain fatty acids and
their association with signalling pathways in inflammation, glucose
and lipid metabolism. Int J Mol Sci. 21(6356)2020.PubMed/NCBI View Article : Google Scholar
|
|
26
|
den Besten G, Bleeker A, Gerding A, van
Eunen K, Havinga R, van Dijk TH, Oosterveer MH, Jonker JW, Groen
AK, Reijngoud DJ and Bakker BM: Short-Chain fatty acids protect
against high-fat diet-induced obesity via a PPARγ-Dependent switch
from lipogenesis to fat oxidation. Diabetes. 64:2398–2408.
2015.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Donnelly KL, Smith CI, Schwarzenberg SJ,
Jessurun J, Boldt MD and Parks EJ: Sources of fatty acids stored in
liver and secreted via lipoproteins in patients with nonalcoholic
fatty liver disease. J Clin Invest. 115:1343–1351. 2005.PubMed/NCBI View
Article : Google Scholar
|
|
28
|
Wolever TM, Brighenti F, Royall D, Jenkins
AL and Jenkins DJ: Effect of rectal infusion of short chain fatty
acids in human subjects. Am J Gastroenterol. 84:1027–1033.
1989.PubMed/NCBI
|
|
29
|
de la Cuesta-Zuluaga J, Mueller NT,
Corrales-Agudelo V, Velásquez-Mejía EP, Carmona JA, Abad JM and
Escobar JS: Metformin is associated with higher relative abundance
of mucin-degrading akkermansia muciniphila and several short-chain
fatty acid-producing microbiota in the gut. Diabetes Care.
40:54–62. 2017.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Juanola O, Ferrusquía-Acosta J,
García-Villalba R, Zapater P, Magaz M, Marín A, Olivas P, Baiges A,
Bellot P, Turon F, et al: Circulating levels of butyrate are
inversely related to portal hypertension, endotoxemia, and systemic
inflammation in patients with cirrhosis. FASEB J. 33:11595–11605.
2019.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Aoki R, Onuki M, Hattori K, Ito M, Yamada
T, Kamikado K, Kim YG, Nakamoto N, Kimura I, Clarke JM, et al:
Commensal microbe-derived acetate suppresses NAFLD/NASH development
via hepatic FFAR2 signalling in mice. Microbiome.
9(188)2021.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Tilg H, Adolph TE and Moschen AR: Multiple
parallel hits hypothesis in nonalcoholic fatty liver disease:
Revisited after a decade. Hepatology. 73:833–842. 2021.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Mridha AR, Wree A, Robertson AAB, Yeh MM,
Johnson CD, Van Rooyen DM, Haczeyni F, Teoh NC, Savard C, Ioannou
GN, et al: NLRP3 inflammasome blockade reduces liver inflammation
and fibrosis in experimental NASH in mice. J Hepatol. 66:1037–1046.
2017.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Alisi A, Carpino G, Oliveira FL, Panera N,
Nobili V and Gaudio E: The role of tissue macrophage-mediated
inflammation on NAFLD pathogenesis and its clinical implications.
Mediators Inflamm. 2017(8162421)2017.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Robinson SM and Mann DA: Role of nuclear
factor kappa B in liver health and disease. Clin Sci (Lond).
118:691–705. 2010.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Tomita K, Tamiya G, Ando S, Ohsumi K,
Chiyo T, Mizutani A, Kitamura N, Toda K, Kaneko T, Horie Y, et al:
Tumour necrosis factor alpha signalling through activation of
Kupffer cells plays an essential role in liver fibrosis of
non-alcoholic steatohepatitis in mice. Gut. 55:415–424.
2006.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Alaaeddine N, Sidaoui J, Hilal G, Serhal
R, Abedelrahman A and Khoury S: TNF-α messenger ribonucleic acid
(mRNA) in patients with nonalcoholic steatohepatitis. Eur Cytokine
Netw. 23:107–111. 2012.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Seo YY, Cho YK, Bae JC, Seo MH, Park SE,
Rhee EJ, Park CY, Oh KW, Park SW and Lee WY: Tumor necrosis
factor-α as a predictor for the development of nonalcoholic fatty
liver disease: A 4-year follow-up study. Endocrinol Metab (Seoul).
28:41–45. 2013.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Machado MG, Sencio V and Trottein F:
Short-chain fatty acids as a potential treatment for infections: A
closer look at the lungs. Infect Immun. 89(e0018821)2021.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Wang S, Lv D, Jiang S, Jiang J, Liang M,
Hou F and Chen Y: Quantitative reduction in short chain fatty
acids, especially butyrate, contributes to the progression of
chronic kidney disease. Clin Sci (Lond). 133:1857–1870.
2019.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Yang T, Yang H, Heng C, Wang H, Chen S, Hu
Y, Jiang Z, Yu Q, Wang Z, Qian S, et al: Amelioration of
non-alcoholic fatty liver disease by sodium butyrate is linked to
the modulation of intestinal tight junctions in db/db mice. Food
Funct. 11:10675–10689. 2020.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Deng M, Qu F, Chen L, Liu C, Zhang M, Ren
F, Guo H, Zhang H, Ge S, Wu C and Zhao L: SCFAs alleviated
steatosis and inflammation in mice with NASH induced by MCD. J
Endocrinol. 245:425–437. 2020.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Liedtke C and Trautwein C: The role of TNF
and Fas dependent signaling in animal models of inflammatory liver
injury and liver cancer. Eur J Cell Biol. 91:582–589.
2012.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Li KZ, Liao ZY, Li YX, Ming ZY, Zhong JH,
Wu GB, Huang S and Zhao YN: A20 rescues hepatocytes from apoptosis
through the NF-κB signaling pathway in rats with acute liver
failure. Biosci Rep. 39(BSR20180316)2019.PubMed/NCBI View Article : Google Scholar
|
|
45
|
García-Ruiz I, Rodríguez-Juan C,
Díaz-Sanjuan T, del Hoyo P, Colina F, Muñoz-Yagüe T and
Solís-Herruzo JA: Uric acid and anti-TNF antibody improve
mitochondrial dysfunction in ob/ob mice. Hepatology. 44:581–591.
2006.PubMed/NCBI View Article : Google Scholar
|
